<em>FLT3</em> mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to <em>Targeted Oncology</em> about the cause of reimbursement issues and how the problem affects all parties involved.
FLT3mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke toTargeted Oncologyabout the cause of reimbursement issues and how the problem affects all parties involved.
Historically,FLT3mutation analyses were processed slowly, and fewer tests were being ordered. Today’s laboratories, however, often operate on a 24-hour basis to handle a large number of tests in a shorter period of time. For these expedient labs, the cost of testing is much higher. Such expenses are not covered for reimbursement, says Clark.
By educating those involved in the testing process, including laboratories, physicians, and payers, a consensus can be reached around a more appropriate turnaround time forFLT3tests. Such education will allow physicians enough time to make clinical decisions that are best for their patients but also help the laboratories maintain a reputation for efficientFLT3mutation analysis. In turn, finding solutions may decrease costs for payers.
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More